AusperBio Raises $50 Million in Series B+ to Advance Functional Cure for Chronic Hepatitis B

AusperBio Raises $50 Million in Series B+ to Advance Functional Cure for Chronic Hepatitis B

SAN FRANCISCO, May 28, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), today…

AusperBio Raises $50M in Series B+ Funding

AusperBio, a San Francisco, CA- and Hangzhou, China-based privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies, raised $50M in Series B+ funding. The round was led by an existing undisclosed investor, with participation from Qiming Venture Partners, CDH Investments, Genesis Capital, YuanBio Venture Capital, HanKang Capital, and Sherpa Capital. The company intends to use […] The post Ausper…